Deep dives, evidence grades, and clinical tools, all in one place.
Practice Signal
ADHD Pharmacotherapy: Stimulants, Nonstimulants, and Mortality
Psychiatry3 sources · Updated Nov 16, 2026
This review helps pharmacists frame ADHD as a condition with measurable mortality risk and place transdermal d-amphetamine and viloxazine ER within a monitoring-centered selection approach.
Bottom Line
Attention-deficit/hyperactivity disorder (ADHD) carries a consistent excess mortality signal driven largely by suicide and injury, so pharmacists can support treatment engagement and pair any stimulant or nonstimulant choice, including the d-amphetamine transdermal system (d-ATS) or viloxazine extended-release (ER), with structured suicidality, comorbidity, and cardiovascular monitoring, while not overstating the observational link between medication and survival.
1.71
HR, all-cause mortality in ADHD
1.89
HR, suicide in ADHD
0.75
HR, mortality with medication
17.6%
viloxazine ER AE discontinuation
State of Play
ADHD is associated with higher all-cause, suicide, injury, and natural-cause mortality, though the magnitude varies widely across settings. Stimulants remain first-line in children and adults, and nonstimulants serve as alternatives when stimulants are ineffective, contraindicated, or not tolerated. The newer agents reviewed here broaden delivery and mechanism options but rest on short-term or uncontrolled data.
🔒
Full Analysis: Subscribers Only
The complete evidence synthesis, practice recommendations, and open questions.
What Changed
How It Fits the Guidelines
Effect chart & evidence comparison
Evidence at a Glance
Practice Considerations
Open Questions
Founding member rate
$8/month. Cancel anytime.
One subscription unlocks this Practice Signal, every other Signal, and every deep analysis we publish, plus PDF reports.
Each Practice Signal is built from our published deep analyses and checked for clinical accuracy before it goes live.
Not medical advice. PharmD Signal provides educational synthesis of published pharmacy and medical literature for practicing pharmacists. It is not a treatment recommendation for any individual patient; clinical decisions remain the responsibility of the treating clinician exercising independent professional judgment.